SEARCH

SEARCH BY CITATION

References

  • ABDEL-RAHMAN, A., SHETTY, A.K. & ABOU-DONIA, M.B. (2002). Disruption of the blood–brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of Gulf-War syndrome. Neurobiol. Dis., 10, 306326.
  • ABRAMS, P., CARDOZO, L., FALL, M., GRIFFITHS, D., ROSIER, P., ULMSTEN, U., VAN KERREBROECK, P., VICTOR, A. & WEIN, A. (2002). The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol. Urodyn., 21, 167178.
  • ANAGNOSTARAS, S.G., MURPHY, G.G., HAMILTON, S.E., MITCHELL, S.L., RAHNAMA, N.P., NATHANSON, N.M. & SILVA, A.J. (2003). Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci., 6, 5158.
  • ANDERSON, R.U., MOBLEY, D., BLANK, B., SALTZSTEIN, D., SUSSET, J. & BROWN, J.S. (1999). Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J. Urol., 161, 18091812.
  • ANDERSSON, K.-E. (1984). Clinical pharmacology of terodiline. Scand. J. Urol. Nephrol. Suppl., 87, 1320.
  • ANDERSSON, K.-E. (1988). Current concepts in the treatment of disorders of micturition. Drugs, 35, 477494.
  • ANDERSSON, K.-E. (2004). Antimuscarinics for treatment of overactive bladder. Lancet Neurol., 3, 4653.
  • ANDERSSON, K.E., APPELL, R., AWAD, S., CHAPPLE, C., DRUTZ, H., FINKBEINER, A., HAAB, F. & VELA NAVARRETE, R. (2002). Pharmacological treatment of urinary incontinence. In: Incontinence, 2nd International Consultation on Incontinence. ed. Abrams, P., Cardozo, L., Khoury, S. & Wein, A., pp. 479511. Plymouth, U.K.: Plymbridge Distributors Ltd.
  • ANDERSSON, K.-E., APPELL, R., CARDOZO, L., CHAPPLE, C., DRUTZ, H., FOURCROY, J., VELA NAVARETTE, R., NISHIZAWA, O. & WEIN, A. (2005). Pharmacological treatment of urinary incontinence. In: Incontinence, 3rd International Consultation on Incontinence. ed. Abrams, P., Khoury, S. & Wein, A., Editions 21, pp. 811854. France: Health Publication Ltd.
  • ANDERSSON, K.-E., APPELL, R., CARDOZO, L.D., CHAPPLE, C., DRUTZ, H.P., FINKBEINER, A.E., HAAB, F. & VELA NAVARRETE, R. (1999). The pharmacological treatment of urinary incontinence. BJU Int., 84, 923947.
  • ANDERSSON, K.E. & CHAPPLE, C.R. (2001). Oxybutynin and the overactive bladder. World J. Urol., 19, 319323.
  • ANDERSSON, K.-E. & YOSHIDA, M. (2003). Antimuscarinics and the overactive detrusor – which is the main mechanism of action? Eur. Urol., 43, 15.
  • APPELL, R.A., ABRAMS, P., DRUTZ, H.P., VAN KERREBROECK, P., MILLARD, R. & WEIN, A. (2001). Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J. Urol., 19, 141147.
  • APPELL, R.A., CHANCELLOR, M.B., ZOBRIST, R.H., THOMAS, H. & SANDERS, S.W. (2003). Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin. Proc., 78, 696702.
  • ARMSTRONG, R.B., LIBER, K.M. & PETERS, K.M. (2005). Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. Int. Urol. Nephrol., 37, 247252.
  • BALLABH, P., BRAUN, A. & NEDERGAARD, M. (2004). The blood–brain barrier: an overview: structure, regulation, clinical implications. Neurobiol. Dis., 16, 113.
  • BARKIN, J., CORCOS, J., RADOMSKY, S., JAMMAL, M.-P., MICELI, P.C., REIZ, J.L., HARSANYI, Z. & DARKE, AC. (2004). A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin. Ther., 26, 10261036.
  • BAUM, B.J. (1993). Principles of saliva secretion. Ann. N. Y. Acad. Sci., 694, 1723.
  • BEROUKAS, D., GOODFELLOW, R., HISCOCK, J., JONSSON, R., GORDON, T.P. & WATERMAN, S.A. (2002). Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjögren's syndrome. Lab. Invest., 82, 203210.
  • BIRDER, L.A., BARRICK, S.R., ROPPOLO, J.R., KANAI, A.J., DEGROAT, W.C., KISS, S. & BUFFINGTON, C.A. (2003). Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from the bladder urothelium. Am. J. Physiol. Renal. Physiol., 285, F423F429.
  • BODICK, N.C., OFFEN, W.W., LEVEY, A.I., CUTLER, N.R., GAUTHIER, S.G., SATLIN, A., SHANNON, H.E., TOLLEFSON, G.D., RASMUSSEN, K., BYMASTER, F.P., HURLEY, D.J., POTTER, W.Z. & PAUL, S.M. (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol., 54, 465473.
  • BOGNAR, I.T., ALTES, U., BEINHAUER, C., KESSLER, I. & FUDER, H. (1992). A muscarinic receptor different from the M1, M2, M3 and M4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn-Schmiedeberg's Arch. Pharmacol., 345, 611618.
  • BOGNAR, I.T., WESNER, M.T. & FUDER, H. (1990). Muscarinic receptor types mediating autoinhibition of acetylcholine release and sphincter contraction in the guinea-pig iris. Naunyn-Schmiedeberg's Arch Pharmacol., 341, 2229.
  • BRAVERMAN, A.S., LUTHIN, G.R. & RUGGIERI, M.R. (1998). M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am. J. Physiol., 275, R1654R1660.
  • BRAVERMAN, A.S. & RUGGIERI SR, M.R. (2003). Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am. J. Physiol. Regul. Integr. Comp. Physiol., 285, R701R708.
  • BYMASTER, F.P., CARTER, P.A., YAMADA, M., GOMEZA, J., WESS, J., HAMILTON, S.E., NATHANSON, N.M., MCKINZIE, D.L. & FELDER, C.C. (2003). Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. Neurosci., 17, 14031410.
  • CAULFIELD, M.P. (1993). Muscarinic receptors – characterization, coupling and function. Pharmacol. Ther., 58, 319379.
  • CAULFIELD, M.P. & BIRDSALL, N.J.M. (1998). International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev., 50, 279290.
  • CHAPPLE, C.R. (2000). Muscarinic receptor antagonists in the treatment of overactive bladder. Urology., 55 (Suppl. 5A), 3346.
  • CHAPPLE, C.R. (2001). Tolterodine once daily: selectivity for the bladder over effects on salivation compared to Ditropan XL. J. Urol., 165 (5 Suppl), 253 (Abstract 1040).
  • CHAPPLE, C., STEERS, W., NORTON, P., MILLARD, R., KRALIDIS, G., GLAVIND, K. & ABRAMS, P. (2005). A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int., 95, 9931001.
  • CHAPPLE, C.R. & ABRAMS, P. (2005). Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur. Urol., 48, 102109.
  • CHESS-WILLIAMS, R. (2002). Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton. Autacoid. Pharmacol., 22, 133145.
  • CHESS-WILLIAMS, R., CHAPPLE, C.R., YAMANISHI, T., YASUDA, K. & SELLERS, D.J. (2001). The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharmacol., 21, 243248.
  • CHIBA, T., BHARUCHA, A.E., THOMFORDE, G.M., KOST, L.J. & PHILLIPS, S.F. (2002). Model of rapid gastrointestinal transit in dogs: effects of muscarinic antagonists and a nitric oxide synthase inhibitor. Neurogastroenterol. Motil., 14, 535541.
  • CHOPPIN, A. & EGLEN, R.M. (2001). Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br. J. Pharmacol., 132, 835842.
  • CHU, F.M., DMCHOWSKI, R.R., LAMA, D.J., ANDERSON, R.U. & SAND, P.K. (2005). Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am. J. Obstet. Gynecol., 192, 18491854.
  • CLAXTON, A.J., CRAMER, J. & PIERCE, C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clin. Ther., 23, 12961310.
  • CLEMETT, D. & JARVIS, B. (2001). Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging, 18, 277304.
  • COLECRAFT, H.M., EGAMINO, J.P., SHARMA, V.K. & SHEU, S.-S. (1998). Signaling mechanisms underlying muscarinic receptor-mediated increase in contraction rate in cultured heart cells. J. Biol. Chem., 273, 3215832166.
  • COLLISON, D.J., COLEMAN, R.A., JAMES, R.S., CAREY, J. & DUNCAN, G. (2000). Characterization of muscarinic receptors in human lens cells by pharmacologic and molecular techniques. Invest. Ophthalmol. Vis. Sci., 41, 26332641.
  • CULP, D.J., LUO, W., RICHARDSON, L.A., WATSON, G.E. & LATCHNEY, L.R. (1996). Both M1 and M3 receptors regulate exocrine secretion by mucous acini. Am. J. Physiol. Cell Physiol., 271, C1963C1972.
  • DE GROAT, W.C. (1997). A neurologic basis for the overactive bladder. Urology, 50 (Suppl. 6A), 3652.
  • DHEIN, S., VAN KOPPEN, C.J. & BRODDE, O.-E. (2001). Muscarinic receptors in the mammalian heart. Pharmacol. Res., 44, 161182.
  • DIEFENBACH, K., DONATH, F., MAURER, A., BRAVO, S.Q., WERNECKE, K.-D., SCHWANTES, U., HASELMANN, J. & ROOTS, I. (2003). Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin. Drug. Invest., 23, 395404.
  • DIOKNO, A.C., APPELL, R.A., SAND, P.K., DMOCHOWSKI, R.R., GBUREK, B.M., KLIMBERG, I.W. & KELL, S.H. (2003). Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations opf oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc., 78, 687695.
  • DOBREV, D., KNUSCHKE, D., RICHTER, F., WETTWER, E., CHRIST, T., KNAUT, M. & RAVENS, U. (2003). Functional identification of M1 and M3 muscarinic acetylcholine receptors in human atrial myocytes: influence of chronic atrial fibrillation [abstract]. Naunyn-Schmiedeberg's Arch. Pharmacol., 367 (Suppl.1), R94.
  • DONNELLAN, C.A., FOOK, L. & PLAYFER, J.R. (1997). Oxybutynin and cognitive dysfunction. BMJ, 315, 13631364.
  • DOUCHAMPS, J., DERENNE, F., STOCKIS, A., GANGJI, D., JUVENT, M. & HERCHUELZ, A. (1988). The pharmacokinetics of oxybutynin in man. Eur. J. Clin. Pharmacol., 35, 515520.
  • DUVVURI, S., MAJUMAR, S. & MITRA, A.K. (2003). Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther., 3, 4556.
  • EGLEN, R.M. (2001). Muscarinic receptors and gastrointestinal tract smooth muscle function. Life Sci., 68, 25732578.
  • EGLEN, R.M. & HARRIS, G.C. (1993). Selective inactivation of muscarinic M2 and M3 receptors in guinea-pig ileum and atria in vitro. Br. J. Pharmacol., 109, 946952.
  • EHLERT, F.J., GRIFFIN, M.T., ABE, D.M., VO, T.H., TAKETO, M.M., MANABE, T. & MATSUI, M. (2005). The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J. Pharmacol. Exp. Ther., 313, 368378.
  • ESPOSITO, P., GHEORGHE, D., KANDERE, K., PANG, X., CONNOLLY, R., JACOBSON, S. & THEOHARIDES, T.C. (2001). Acute stress increases permeability of the blood–brain-barrier through activation of brain mast cells. Brain Res., 888, 117127.
  • FETSCHER, C., FLEICHMAN, M., SCHMIDT, M., KREGE, S. & MICHEL, M.C. (2002). M3 muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol., 136, 641643.
  • FISHER, A., PITTEL, Z., HARING, R., BAR-NER, N., KLIGER-SPATZ, M., NATAN, N., EGOZI, I., SONEGO, H., MARCOVITCH, I. & BRANDEIS, R. (2003). M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease. J. Mol. Neurosci., 20, 349356.
  • FRY, C.H., IKEDA, Y., HARVEY, R., WU, C. & SUI, G.-P. (2004). Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology, 63 (Suppl. 3A), 2431.
  • GAUTAM, D., HEARD, T.S., CUI, Y., MILLER, G., BLOODWORTH, L. & WESS, J. (2004). Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice. Mol. Pharmacol., 66, 260267.
  • GERSHON, M.D. (2003). Serotonin and its implication for the management of irritable bowel syndrome. Rev. Gastroenterol. Disord., 3 (Suppl. 2), S25S34.
  • GIL, D.W., KRAUSS, H.A., BOGARDUS, A.M. & WOLDEMUSSIE, E. (1997). Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation. Invest. Ophthalmol. Vis. Sci., 38, 14341442.
  • GILLBERG, P.G., SUNDQUIST, S. & NILVEBRANT, L. (1998). Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur. J. Pharmacol., 349, 285292.
  • GILLESPIE, J.I. (2004a). The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int., 93, 478483.
  • GILLESPIE, J.I. (2004b). Modulation of autonomous contractile activity in the isolated whole bladder of the guinea pig. BJU Int., 93, 393400.
  • GILLESPIE, J.I., HARVEY, I.J. & DRAKE, M.J. (2003). Agonist- and nerve-induced phasic activity in the isolated whole bladder of the guinea pig: evidence for two types of bladder activity. Exp. Physiol., 88, 343357.
  • GOMEZ, A., MARTOS, F., BELLIDO, I., MARQUEZ, E., GARCIA, A.J., PAVIA, J. & DE LA CUESTA, F.S. (1992). Muscarinic receptor subtypes in human and rat colon smooth muscle. Biochem. Pharmacol., 43, 24132419.
  • GOMEZA, J., SHANNON, H., KOSTENIS, E., FELDER, C., ZHANG, L., BRODKIN, J., GRINBERG, A., SHENG, H. & WESS, J. (1999). Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 96, 16921697.
  • GOSLING, J.A., DIXON, J.S. & JEN, P.Y. (1999). The distribution of noradrenergic nerves in the human lower urinary tract: a review. Eur. Urol., 36 (Suppl. 1), 2330.
  • GUPTA, S.K. & SATHYAN, G. (1999). Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J. Clin. Pharmacol., 39, 289296.
  • HAAB, F., STEWART, L. & DWYER, P. (2004). Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol., 45, 420429.
  • HABGOOD, M.D., BEGLEY, D.J. & ABBOTT, N.J. (2000). Determinants of passive drug entry into the central nervous system. Cell Mol. Neurobiol., 20, 231253.
  • HALASKA, M., RALPH, G., WIEDEMANN, A., PRIMUS, G., BALLERING-BRÜHL, B., HÖFNER, K. & JONAS, U. (2003). Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J. Urol., 20, 392399.
  • HARDOUIN, S.N., RICHMOND, K.N., ZIMMERMAN, A., HAMILTON, S.E., FEIGL, E.O. & NATHANSON, N.M. (2002). Altered cardiovascular responses in mice lacking the M1 muscarinic acetylcholine receptor. J. Pharmacol. Exp. Ther., 301, 129137.
  • HEGDE, S.S., CHOPPIN, A., BONHAUS, D., BRIAUD, S., LOEB, M., MOY, T.M., LOURY, D. & EGLEN, RM. (1997). Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol., 120, 14091418.
  • HEGDE, S.S. & EGLEN, R.M. (1999). Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci., 64, 419428.
  • HELLGREN, I., MUSTAFA, A., RIAZI, M., SULIMAN, I., SYLVÉN, C. & ADEM, A. (2000). Muscarinic M3 receptor subtype gene expression in the human heart. Cell Mol. Life Sci., 57, 175180.
  • HULME, E.C., BIRDSALL, N.J.M. & BUCKLEY, N.J. (1990). Muscarinic receptor subtypes. Ann. Rev. Pharmacol. Toxicol., 30, 633673.
  • IGAWA, Y., ZHANG, X., NISHIZAWA, O., UMEDA, M., IWATA, A., TAKETO, M.M., MANABE, T., MATSUI, M. & ANDERSSON, K.E. (2004). Cystometric findings and in mice lacking muscarinic M2 or M3 receptors. J Urol., 172, 24602464.
  • IKEDA, K., KOBAYASHI, S., SUZUKI, M., MIYATA, K., TAKEUCHI, M., YAMADA, T. & HONDA, K. (2002). M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg's Arch Pharmacol., 366, 97103.
  • ISHIZAKA, N., NODA, M., YOKOYAMA, S., KAWASAKI, K., YAMAMOTO, M. & HIGASHIDA, H. (1998). Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res., 787, 344347.
  • ISLAM, M.A., NOJIMA, H. & KIMURA, I. (1998). Muscarinic M1 receptor activation reduces maximum upstroke velocity of action potential in mouse right atria. Eur. J. Pharmacol., 346, 227236.
  • JUMBLATT, J.E. & HACKMILLER, R.C. (1994). M2-type muscarinic receptors mediate prejunctional inhibition of norepinephrine release in the human iris-ciliary body. Exp. Eye. Res., 58, 175180.
  • KANNO, H., HORIKAWA, Y., HODGES, R.R., ZOUKHRI, D., SHATOS, M.A., RIOS, J.D. & DARTT, D.A. (2003). Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell secretion. Am. J. Physiol. Cell Physiol., 284, C988C998.
  • KATZ, I.R., SANDS, L.P., BILKER, W., DIFILIPPO, S., BOYCE, A. & D'ANGELO, K. (1998). Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc., 46, 813.
  • KAY, G. & WESNES, K. (2005). Pharmacodynamic effects of darifenacin, a muscarinic M3 selective antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int., 96, 10551062.
  • KERR, P.M., HILLIER, K., WALLIS, R.M. & GARLAND, C.J. (1995). Characterization of muscarinic receptors mediating contractions of circular and longitudinal muscle of human isolated colon. Br. J. Pharmacol., 115, 15181524.
  • KRICHEVSKY, V.P., PAGALA, M.K., VAYDOVSKY, I., DAMER, V. & WISE, G.J. (1999). Function of M3 muscarinic receptors in the rat urinary bladder following partial outlet obstruction. J. Urol., 161, 16441650.
  • LAMPING, K.G., WESS, J., CUI, Y., NUNO, D.W. & FARACI, F.M. (2004). Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler. Thromb. Vasc. Biol., 24, 12531258.
  • LI, M., JOHNSON, C.P., ADAMS, M.B. & SARNA, S.K. (2002). Cholinergic and nitrergic regulation of in vivo giant migrating contractions in rat colon. Am. J. Physiol. Gastrointest. Liver. Physiol., 283, G544G552.
  • LIEBSCH, R., KORNHUBER, M.E., DIETL, D., GRÄFIN VON EINSIEDEL, H. & CONRAD, B. (1996). Blood–CSF barrier integrity in multiple sclerosis. Acta Neurol. Scand., 94, 404410.
  • LIPTON, R.B., KOLODNER, K. & WESNES, K. (2005). Assessment of cognitive function of the elderly population: effects of darifenacin. J. Urol., 173, 493498.
  • LUO, W., LATCHNEY, L.R. & CULP, D.J. (2001). G protein coupling to M1 and M3 muscarinic receptors in sublingual glands. Am. J. Physiol. Cell Physiol., 280, C884C896.
  • MATSUI, M., MOTOMURA, D., FUJIKAWA, T., JIANG, J., TAKAHASHI, S., MANABE, T. & TAKETO, M.M. (2002). Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J. Neurosci., 22, 1062710632.
  • MATSUI, M., MOTOMURA, D., KARASAWA, H., FUJIKAWA, T., JIANG, J., KOMIYA, Y., TAKAHASHI, S. & TAKETO, M.M. (2000). Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc. Natl. Acad. Sci. U.S.A., 97, 95799584.
  • MESSER Jr, W.S., BOHNETT, M. & STIBBE, J. (1990). Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci. Lett., 116, 184189.
  • NAPIER, C. & GUPTA, P. (2002). Darifenacin is selective for the human recombinant M3 receptor subtype [abstract]. Neurourol. Urodyn., 21, A445.
  • NIIHASHI, M., ESUMI, M., KUSUMI, Y., SATO, Y. & SAKURAI, I. (2000). Expression of muscarinic receptor genes in the human coronary artery. Angiology., 51, 295300.
  • NISHIMARU, K., TANAKA, Y., TANAKA, H. & SHIGENOBU, K. (2000). Positive and negative inotropic effects of muscarinic receptor stimulation in mouse left atria. Life Sci., 66, 607615.
  • OLSSON, B. & SZAMOSI, J. (2001). Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin. Pharmacokinet., 40, 227235.
  • PAKULSKI, C., DROBNIK, L. & MILLO, B. (2000). Age and sex as factors modifying the function of the blood–cerebrospinal fluid barrier. Med. Sci. Monit., 6, 314318.
  • PERRY, E.K., KILFORD, L., LEES, A.J., BURN, D.J. & PERRY, R.H. (2003). Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol., 54, 235238.
  • PIETZKO, A., DIMPFEL, W., SCHWANTES, U. & TOPFMEIER, P. (1994). Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur. J. Clin. Pharmacol., 47, 337343.
  • PÖNICKE, K., HEINROTH-HOFFMANN, I. & BRODDE, O.-E. (2003). Demonstration of functional M3-muscarinic receptors in ventricular cardiomyocytes of adult rats. Br. J. Pharmacol., 138, 156160.
  • PONTARI, M.A., BRAVERMAN, A.S. & RUGGIERI SR, M.R. (2004). The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am. J. Physiol. Regul. Integr. Comp. Physiol., 286, R874R880.
  • POYER, J.F., GABELT, B.T. & KAUFMAN, P.L. (1994). The effect of muscarinic agonists and selective receptor subtype antagonists on the contractile response of the isolated Rhesus monkey ciliary muscle. Exp. Eye Res., 59, 729736.
  • Prescribing Information (2004). Sanctura trospium chloride 20 mg tablets, http:www.sanctura.comSanctura_Prescribing_Information.pdf.
  • Prescribing Information, VESIcare (US) (2004) http:www.vesicare.compdfvesicareprescribing_info.pdf.
  • Product Information, Detrol (US) (2005) http:www.pfizer.comdownloaduspi_detrol.pdf.
  • Product Information, Detrol LA (US) (2005) http:pfizer.compfizerdownloaduspi_detrol_la.pdf.
  • Product Information, Enablex (US) (2005) http:www.pharma.us.novartis.comproductpipdfenablex.pdf.
  • Product Information, Ditropan (US) (2005) http:www.ditropanxl.comprofessionalfull_presc.htm.
  • Product Information. Ditropan/Ditropan XL (2004) http:www.orthomcneil.comproductspipdfsLg%20Ditropan%20PI.pdf, http:www.orthomcneil.comproductspipdfsditropanxl.pdf.
  • RICHTER, A., ANTON, S.E., KOCH, P. & DENNETT, S.L. (2003). The impact of reducing dose frequency on health outcomes. Clin. Ther., 25, 23072335.
  • RODEN, D.M. (2004). Drug-induced prolongation of the QT interval. N. Engl. J. Med., 350, 10131022.
  • SEEGER, T., FEDOROVA, I., ZHENG, F., MIYAKAWA, T., KOUSTOVA, E., GOMEZA, J., BASILE, A.S., ALZHEIMER, C. & WESS, J. (2004). M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J. Neurosci., 24, 1011710127.
  • SERRA, D.B., AFFRIME, M.B., BEDIGIAN, M.P., GREIG, G., MILOSAVLJEV, S., SKERJANEL, A. & WANG, Y. (2005). QT and QTc interval with standard and supra-therapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J. Clin. Pharm., 45, 10381047.
  • SHADE, D.L., CLARK, A.F. & PANG, I.-H. (1996). Effects of muscarinic agents on cultured human trabecular meshwork cells. Exp. Eye Res., 62, 201210.
  • SMULDERS, R.A., KRAUWINKEL, W.J., SWART, P.J. & HUANG, M. (2004). Pharmacokinetics and safety of solifenacin succinate in healthy young men. J. Clin. Pharmacol., 44, 10231033.
  • SO, I., YANG, D.K., KIM, H.J., MIN, K.W., KANGE, T.M., KIM, S.J., KIM, K.W., PARTK, K.H., JEON, J.H., CHOI, K.H. & KIM, I.G. (2003). Five subtypes of muscarinic receptors are expressed in gastric smooth muscles of guinea pig. Exp. Mol. Med., 35, 4652.
  • SOMOGYI, G.T. & DE GROAT, W.C. (1999). Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci., 64, 411418.
  • SOMOGYI, G.T., TANOWITZ, M., ZERNOVA, G. & DE GROAT, W.C. (1996). M1 muscarinic receptor -induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. J. Physiol., 496, 245254.
  • SOMOGYI, G.T., ZERNOVA, G.V., YOSHIYAMA, M., ROCHA, J.N., SMITH, C.P. & DE GROAT, W.C. (2003). Change in muscarinic modulation of transmitter release in the rat urinary bladder after spinal cord injury. Neurochem. Int., 43, 7377.
  • STARR, J.M., WARDLAW, J., FERGUSON, K., MACLULLICH, A., DEARY, I.J. & MARSHALL, I. (2003). Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry., 74, 7076.
  • STEERS, W., CORCOS, J., FOOTE, J. & KRALIDIS, G. (2005). An investigation of dose titration with darifenacin, an M3 selective receptor antagonist. BJU Int., 95, 580586; Erratum in: BJU Int., 95, 1385–1386.
  • STENGEL, P.W., GOMEZA, J., WESS, J. & COHEN, M.L. (2000). M2 and M4 receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J. Pharmacol. Exp. Ther., 292, 877885.
  • STENGEL, P.W., YAMADA, M., WESS, J. & COHEN, M.L. (2002). M3-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am. J. Physiol. Regul. Integr. Comp. Physiol., 282, R1443R1449.
  • STEVENS, L., CHAPPLE, C.R., TOPHILL, P. & CHESS-WILLIAMS, R. (2004a). A comparison of muscarinic receptor-mediated function in the normal and the neurogenic overactive bladder. J Urol., 171, 143 (Abstract 535).
  • STEVENS, L., CHESS-WILLIAMS, R. & CHAPPLE, C.R. (2004b). Muscarinic receptor function in the idiopathic overactive bladder. J Urol., 171, 140141 (Abstract 527).
  • THIEME, H., HILDEBRANDT, J., CHORITZ, L., STRAUSS, O. & WIEDERHOLT, M. (2001). Muscarinic receptors of the M2 subtype in human and bovine trabecular meshwork. Graefe's Arch. Clin. Exp. Ophthalmol., 239, 310315.
  • THOMAS, S., ROMANZI, L. & LHERITIER, K. (2005). Constipation and associated intervention in patients with overactive bladder treated with darifenacin or tolterodine. Int. Urogynecol. J., 16 (Suppl. 2), S101 (Abstract 306).
  • TOBIN, G. (2002). Presynaptic muscarinic receptor mechanisms and submandibular responses to stimulation of the parasympathetic innervation in bursts in rats. Auton. Neurosci., 99, 111118.
  • TOBIN, G., GIGLIO, D. & GÖTRICK, B. (2002). Studies of muscarinic receptor subtypes in salivary gland function in anaesthetized rats. Auton. Neurosci., 100, 19.
  • TRENDELENBURG, A.-U., GOMEZA, J., KLEBROFF, W., ZHOU, H. & WESS, J. (2003). Heterogeneity of presynaptic muscarinic receptors mediating inhibition of sympathetic transmitter release: a study with M2- and M4-receptor-deficient mice. Br. J. Pharmacol., 138, 469480.
  • TUNE, L.E. (2001). Anticholinergic effects of medication in elderly patients. J. Clin. Psychiatry, 62 (Suppl. 21), 1114.
  • TURNER, W.H. & BRADING, A.F. (1997). Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol. Ther., 75, 77110.
  • TZAVARA, E.T., BYMASTER, F.P., FELDER, C.C., WADE, M., GOMEZA, J., WESS, J., MCKINZIE, D.L. & NOMIKOS, G.G. (2003). Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol. Psychiatry, 8, 673679.
  • VAN KERREBROECK, P., KREDER, K., JONAS, U., ZINNER, N. & WEIN, A. (2001). Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology, 57, 414421.
  • VOLPICELLI, L.A. & LEVEY, A.I. (2004). Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog. Brain Res., 145, 5966.
  • WANG, H., HAN, H., ZHANG, L., SHI, H., SCHRAM, G., NATTEL, S. & WANG, Z. (2001). Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol. Pharmacol., 59, 10291036.
  • WANG, P., LUTHIN, G.R. & RUGGIERI, M.R. (1995). Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacol. Exp. Ther., 273, 959966.
  • WANG, Z., SHI, H. & WANG, H. (2004). Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br. J. Pharmacol., 142, 395408.
  • WATSON, E.L., ABEL, P.W., DIJULIO, D., ZENG, W., MAKOID, M., JACOBSON, K.L., POTTER, L.T. & DOWD, F.J. (1996). Identification of muscarinic receptor subtypes in mouse parotid gland. Am. J. Physiol. Cell Physiol., 271, C905C913.
  • WIEDERHOLT, M., SCHÄFER, R., WAGNER, U. & LEPPLE-WIENHUES, A. (1996). Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. German J. Ophthalmol., 5, 146153.
  • WILLMY-MATTHES, P., LEINEWEBER, K., WANGEMANN, T., SILBER, R.E. & BRODDE, O.-E. (2003). Existence of functional M3-muscarinic receptors in the human heart. Naunyn-Schmiedeberg's Arch. Pharmacol., 368, 316319.
  • WOLDEMUSSIE, E., FELDMANN, B.J. & CHEN, J. (1993). Characterization of muscarinic receptors in cultured human iris sphincter and ciliary smooth muscle cells. Exp. Eye Res., 56, 385392.
  • WOMACK, K.B. & HEILMAN, K.M. (2003). Tolterodine and memory: dry but forgetful. Arch. Neurol., 60, 771773.
  • YAMADA, M., MIYAKAWA, T., DUTTAROY, A., YAMANAKA, A., MORIGUCHI, T., MAKITA, R., MCKINZIE, D.L., FELDER, C.C., DENG, C.X., FARACI, F.M. & WESS, J. (2001a). Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature, 410, 207212.
  • YAMADA, M., LAMPING, K.G., DUTTAROY, A., ZHANG, W., CUI, Y., BYMASTER, F.P., OGAWA, M., CHOU, C.J., XIA, B., CRAWLEY, J.N., FELDER, C.C., DENG, C.X. & WESS, J. (2001b). Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 98, 1409614101.
  • YONO, M., YOSHIDA, M., TAKAHASHI, W., INADOME, A. & UEDA, S. (2000). Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle. BJU Int., 86, 719725.
  • YOSHIDA, M., MIYAMAE, K., IWASHITA, H., OTANI, M. & INADOME, A. (2004). Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology, 63 (3 Suppl. 1), 1723.
  • ZHOU, H., MEYER, A., STARKE, K., GOMEZA, J., WESS, J. & TRENDELENBERG, A.U. (2002). Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice. Naunyn-Schmiedeberg's Arch. Pharmacol., 365, 112122.
  • ZINNER, N., TUTTLE, J. & MARKS, L. (2005). Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J. Urol., 23, 248252.